Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

Journal of Pathology

Volumn 236, Issue 3, 2015, Pages 348-359

  Baranski, Zuzanna ^a   Booij, Tijmen H ^a   Cleton Jansen, Anne Marie ^b   Price, Leo S ^a   Van De Water, Bob ^a   Bovée, Judith V M G ^b   Hogendoorn, Pancras C W ^b   Danen, Erik H J ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c OcellO BV   (Netherlands)

Author keywords

3D cell culture; Aven; Chk1 inhibitors; doxorubicin; osteosarcoma

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ADAPTOR PROTEIN; ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHIR 124; DOXORUBICIN; PROTEIN AVEN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; RABUSERTIB; UNCLASSIFIED DRUG; 3-(CARBAMOYLAMINO)-5-(3-FLUOROPHENYL)-N-(3-PIPERIDYL)THIOPHENE-2-CARBOXAMIDE; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; ATR PROTEIN, HUMAN; AVEN PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; THIOPHENE DERIVATIVE; UREA;

ADJUVANT THERAPY; ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; EXTRACELLULAR MATRIX; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS FREE SURVIVAL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; APOPTOSIS; BONE NEOPLASMS; DNA DAMAGE; DNA MICROARRAY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BONE NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PHOSPHORYLATION; PROTEIN KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIOPHENES; UREA;

EID: 84930470918     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4528     Document Type: Article

References (36)

1. Anninga JK, Gelderblom H, Fiocco M, et al., Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; 47: 2431-2445.
2. Rosenberg AE, Cleton-Jansen A-M, Pinieux Gd, et al., Conventional osteosarcoma. In WHO Classification of Tumours of Soft Tissue and Bone. IARC: Lyon, 2013; 282-288.
3. Buddingh EP, Anninga JK, Versteegh MI, et al., Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010; 54: 216-221.
4. Chau BN, Cheng EH, Kerr DA, et al., Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000; 6: 31-40.
5. Kutuk O, Temel SG, Tolunay S, et al., Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. Eur J Cancer 2010; 46: 2494-2505.
6. Hawley RG, Chen Y, Riz I, et al., An integrated bioinformatics and computational biology approach identifies new BH3-only protein candidates. Open Biol J 2012; 5: 6-16.
7. Guo JY, Yamada A, Kajino T, et al., Aven-dependent activation of ATM following DNA damage. Curr Biol 2008; 18: 933-942.
8. Mordes DA, Cortez D,. Activation of ATR and related PIKKs. Cell Cycle 2008; 7: 2809-2812.
9. Kurz EU, Lees-Miller SP,. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004; 3: 889-900.
10. Bartek J, Lukas J,. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
11. Garrett MD, Collins I,. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 2011; 32: 308-316.
12. Paydas S, Tanriverdi K, Yavuz S, et al., Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003; 14: 1045-1050.
13. Choi J, Hwang YK, Sung KW, et al., Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia. Leuk Res 2006; 30: 1019-1025.
14. Eissmann M, Melzer IM, Fernandez SB, et al., Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms. Oncogene 2013; 32: 2586-2591.
15. Kuijjer ML, Rydbeck H, Kresse SH, et al., Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012; 51: 696-706.
16. Mohseny AB, Szuhai K, Romeo S, et al., Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
17. Mohseny AB, Machado I, Cai Y, et al., Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011; 91: 1195-1205.
18. Ottaviano L, Schaefer KL, Gajewski M, et al., Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010; 49: 40-51.
19. Greco WR, Bravo G, Parsons JC,. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.
20. Borisy AA, Elliott PJ, Hurst NW, et al., Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003; 100: 7977-7982.
21. Figueroa B, Jr., Chen S, Oyler GA, et al., Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions. Biotechnol Bioeng 2004; 85: 589-600.
22. Kastan MB, Bartek J,. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
23. Wilsker D, Petermann E, Helleday T, et al., Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci USA 2008; 105: 20752-20757.
24. Bartek J, Falck J, Lukas J,. CHK2 kinase-a busy messenger. Nat Rev Mol Cell Biol 2001; 2: 877-886.
25. Kaneko YS, Watanabe N, Morisaki H, et al., Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 1999; 18: 3673-3681.
26. Jazayeri A, Falck J, Lukas C, et al., ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8: 37-45.
27. Cuadrado M, Martinez-Pastor B, Murga M, et al., ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med 2006; 203: 297-303.
28. Harper JW, Elledge SJ,. The DNA damage response: ten years after. Mol Cell 2007; 28: 739-745.
29. McNeely S, Beckmann R, Bence Lin AK,. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014; 142: 1-10.
30. Itamochi H, Nishimura M, Oumi N, et al., Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2014; 24: 61-69.
31. Landau HJ, McNeely SC, Nair JS, et al., The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11: 1781-1788.
32. 2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70: 4972-4981.
33. Sausville E, Lorusso P, Carducci M, et al., Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73: 539-549.
34. 2 every 21 days in patients with cancer. Invest New Drugs 2013; 31: 136-144.
35. Calvo E, Chen VJ, Marshall M, et al., Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs 2014; 5: 955-968.
36. Luetke A, Meyers PA, Lewis I, et al., Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev 2014; 40: 523-532.